ÍøºìºÚÁÏ

Skip to main content

Nicole M Iovine, MD, PhD

Infectious Disease Specialist

Photo of Nicole M Iovine

Research at a glance

Top areas of exploration

  • Anti-Bacterial Agents , 11 publications
  • COVID-19 , 6 publications
  • COVID-19 Drug Treatment , 4 publications
  • Influenza, Human , 4 publications

Research activity

47 publications

3,450 citations

Why is this important?

Focus

I am trained as both an Infectious Disease specialist and as an expert in innate defense against bacterial infection, with a focus on Gram-negative organisms.  As an Infectious Disease specialist, I am particularly interested in treatment approaches to multidrug-resistant Gram-negative infections.  As a researcher, I study the innate defenses against these types of infections.  In one project, I study the Bactericidal/Permeability-Increasing protein (BPI) - an endogenous antibiotic found in neutrophils and available in recombinant form. BPI has potent activity against Gram-negative bacteria, including multidrug-resistant clinical isolates I collect.

I have also studied emerging infections, such as chikungunya, Zika and seasonal influenza. I was engaged in two NIH-sponsored clinical trials for the treatment of seasonal influenza with immune plasma and triple therapy (ribivirin, oseltamivir and amantadine). I was the Principal Investigator for UF site of the NIH-sponsored Adaptive COVID-19 Treatment Trials (ACTT), which identified remdesivir and baricitinib as important agents for the treatment of COVID patients. Most recently, I am the Principal Investigator for the UF site of the STOMP monkeypox clinical trial, and for the Accelerating COVID-19 Therapeutic Interventions and Vaccines clinical trials (ACTIV4a and ACTIV4d).

Active clinical trials

My publications

47 publications

2021

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.

The New England journal of medicine

•

2021

Disseminated genitourinary histoplasmosis in a patient with AIDS with negative urine antigen testing.

BMJ case reports

•

2021

Dissemination mechanisms of NDM genes in hospitalized patients.

JAC-antimicrobial resistance

•

2021

Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial.

The Lancet. Respiratory medicine

•

2020

Evaluation of patient risk factors for infection with carbapenem-resistant Enterobacteriaceae.

American journal of infection control

•